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Assessing Efficiency in the Pharmaceutical Sector of
Nigeria
Efayena O. Obukohwo1 , Enoh H. Olele2 and Patricia N. Buzugbe3
The study analyses, empirically, the efficiency of the Pharmaceutical sector
in Nigeria. Employing a balanced panel of 20 pharmaceutical firms between
2012 and 2016, the paper uses a non-parametric technique (Data Envelopment Analysis) to analyze the firms’ efficiency under the constant returns to
scale (CRS) and variable returns to scale (VRS) assumptions. The results
obtained shows inefficiency in the pharmaceutical sector as it operates under a decreasing return to scale. This calls for an appropriate policy mix to
stimulate the efficiency of the pharmaceutical sector in Nigeria by enhancing research and development (R&D) as ell as regulations within the sector.
Keywords: Data Envelopment Analysis, Efficiency, Firm, Performance, Pharmaceuticals
JEL Classification: D1, L1.
DOI: 10.33429/Cjas.09218.6/6

1.0 Introduction
The pharmaceutical sector in any economy plays a prominent role in the general
health of citizens residing in the country. Nigeria is not an exception. Owing to its
significance in the general welfare of the economy, it is imperative to give serious
attention to issues that concern this sector.
The Nigerian pharmaceutical sector is known to be complex as it involves numerous
players (manufacturers, national regulators, wholesalers and retailers, government
ministries and other stakeholders). This means that there is need for these stakeholders to put in additional effort to create an enabling environment to exploit
the full potentials of the sector. The Pharmaceutical Manufacturers Group of the
Manufacturers Association of Nigeria (PMG-MAN, 2010) asserted that the Nigerian pharmaceutical sector has the potential to be a leader in the production and
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distribution of pharmaceuticals Sub-Saharan Africa, with nine Nigerian pharmaceutical firms (Drugfield Pharmaceuticals Ltd, Emzor Pharmaceutical Industries
Ltd, Evans Medical Plc, Fidson Healthcare Plc, GlaxoSmithKline Nigeria, May
& Baker Nigeria Plc, Mopson Pharmaceutical Industries Ltd, Neimeth International Pharmaceuticals and PZ Cussons Plc) exporting their products to various
ECOWAS countries.

Although Nigeria has a large human capital (approximately 190 million people)
and vast natural resources, the country is still fraught with poverty, diseases and
malnutrition (World Health Organisation, 2013). The World Health Organisation
(WHO) rated Nigeria’s health sector 187th out of 191 members (WHO, 2000). The
poor rating of the sector is due to a lack of standard equipment for production
and storage of pharmaceuticals. As such, only a few of the pharmaceutical firms
in Nigeria have the capacity to participate in the supply of anti-malaria, anti-TB
medicines, anti-retroviral and other pharmaceuticals in international tenders (Lead
Capital Ltd, 2008).

Efficiency in the pharmaceutical sector can be measured using: (i) allocative efficiency, (ii) X-efficiency, (iii) distributional efficiency and (iv) technical efficiency
coefficients. There are abundant empirical studies on efficiency and its determinants in the pharmaceutical sector of developed economies (Praven and Tapan,
2005; Adhikari, 2005; Jiankang, 2014; Chadda, 2006; Gupta, 2007; Chaturvedi
and Chataway, 2006), but there exists a dearth of such studies for developing
countries like Nigeria. The growth of the Nigerian Pharmaceutical industry has
been featured in few empirical studies, but to the best of our knowledge, a comprehensive work on the efficiency of the industry in a multivariate framework has
not been carried out. One of the recent works in this area is that of Wakeel and
Ekundayo (2016). Their emphasis however, was on the determinants of the performance of the pharmaceutical industry in Nigeria. This study aims to fill this
gap by analyzing empirically, the efficiency of the Pharmaceutical sector in Nigeria using a non-parametric technique (Data Envelopment Analysis) for a balanced
panel of 20 pharmaceutical firms between 2012 and 2016.
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The remaining part of the paper is structured as follows; section 2 gives a review
of related literature, section 3 provides the methodology; section 4 analyzes the
results obtained; and section 5 concludes the study with policy recommendations.

2.0 Literature Review
2.1 Theoretical Literature
Efficiency can be gauged in relation to a comparison between observed and optimal values of its output and input in the production process. Among the various
theories of efficiency, the structure conduct and performance (SCP) model stands
out. According to Mari (2009) the SCP model deals with the organization and operation of the free enterprise sector. The framework was derived from taking a neoclassical analysis of markets. It is a combination of empirical studies of industrial
experience and economic theories (Giroh, et al., 2010; Shaik, et al., 2009). There
are two competing hypotheses in the SCP framework: the traditional “structure
performance hypothesis” and “efficient structure hypothesis”. While the structure
performance hypothesis asserts that the degree of market concentration inversely
relates to the degree of competition, both going in opposite directions making
concentrated firms to earn higher profits, the efficiency structure hypothesis states
that the performance of the firm is positively related to its efficiency.
The efficiency theory has been widely adopted in various empirical studies (Demsetz 1973; Berger, 1995; Howard and Pollock, 1999; Cockburn, 2004; Praveen and
Tapan, 2005; Tung, et al., 2010; and Jiankang, 2014). The efficiency hypothesis
suggests that the efficiency of a firm dictates the nature of the relationship between
the performance of the firm and its structure. Simply put, a firm is said to be
highly efficient in relation to close competitors if it can maximize its profit while
reducing its current cost structure and current plant size (or expanding its operations). The firm can also be said to be highly efficient if it can minimize its current
cost structure. In this hypothesis, the X-efficiency argument holds that firms will
have low cost in their production if they possess more productive technologies
(Demsetz, 1973; Brozen, 1982; Gale and Branch 1982). The scale efficiency side of
the debate states that some firms may be more efficient even though they may have
similar technologies and management techniques thus acquiring market shares.
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2.2 Empirical Literature
The issue of efficiency has featured in a number of empirical studies (Ferreira,
2014; Lee, 2012; Park, 2012; Behname, 2012; Sahoo and Mishra, 2012; Mensi and
Zouari, 2011; Giroh, et al, 2010; Shaik, et al, 2009). For instance, Ferreira (2014)
examined the efficiency of the banking industry in the European Union (EU) in
relation to market concentration. Mishra and Vikas (2010), using a modified structure conduct and performance (SCP) model, explored 176 pharmaceutical firms
and arrived at the conclusion that there is a bi-lateral relationship between performance and conduct variables in the selected firms. The findings of the study of
Ferreira (2014) complemented that of Lee (2012) who examined the model in the
Taiwanese CPA industry.
On their part, Mishra and Chandra (2010) employed the data of 52 pharmaceutical
firms in India in search of a measure of efficiency. Their results showed that increasing the selling measures (for example via advertisements and promotions) will
lead to a positive and significant impact on the profit level of the firms. Sarita, et
al (2012) adopted the same model in their examination of the Indonesian banking
industry. While Sahoo and Mishra (2012) explored efficiency in the Indian banking industry, Maudos (1998) examined efficiency in the banking sector of Spain.
Though the study adopted efficient structure hypothesis, the findings corroborated
some of the findings of previous studies on the subject area.
While the majority of literature that adopted SCP model is found in the developed economies and mostly in the banking sector of such countries (Ferreira,
2014; Behname, 2012; Sahoo and Mishra, 2012; Park, 2012; Lee, 2012; Mensi
and Zouari, 2011; Maniatis, 2006), few studies were conducted on pharmaceutical
firms operating in developing economies (Vyas, et al. 2012; Mishra and Chandra,
2010; Mishra and Vikas, 2010; Zhang & Li, 2009). Ogaji et al (2014) showed that
the capacity utilization of the Nigerian pharmaceutical industry increased steadily
but marginally over the period of 1984 to 2014.Furthermore, Ugbam and Okoro
(2017) asserted that larger firms are more efficient in the pharmaceutical industry
in Nigeria. This implies that smaller firms faced with stiff competition from rival
firms will eventually wind up (Olugbenga, 2010).
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3.0 Methodology
3.1 The Data Envelopment Analysis (DEA)
There exist numerous techniques (statistical and econometrical) adopted in both
theoretical and empirical consideration of efficiency. However, in recent years, the
Data Envelopment Analysis (DEA) has become more popular (Zhu, 2002)1 .

The Data Envelopment Analysis (DEA) method was proposed by Charnes et al.,
(1978). Analytically, this methodology employs linear programming to generate
an efficient frontier and related efficiency indicators within homogeneous production units. DEA is a nonparametric method which measures economic efficiency.
It is a linear programming model, assuming no random mistakes, used to measure
technical efficiency. In relation to a firm, an efficient firm is one that produces
a certain quantity of output given a stipulated quantity of inputs. It can also
be expressed as the use of the same quantity or less inputs to produce a given
amount of output compared to other firms in a given strata. This technique has
been explored in many fields including environmental, financial, security, power,
and administration (Kwon and Lee, 2015; Tao et al, 2013; Tsolas and Charles,
2015; Wanke and Barros, 2014; Aristovnik et al, 2014; Fang and Li, 2015; Du et
al, 2014; Lozano, 2015; Azadeh et al, 2015; Omrani, et al, 2015). The technique is
used to evaluate performance across a set of homogeneous production units with
multiple resources and products. From the foregoing, the Nigerian pharmaceutical
industry constitutes the Decision-Making Units (DMUs), which can be treated as
multiproduct firms that transform resources (inputs) into products (outputs). By
adopting the DEA, we seek to find the DMUs that produce the highest output levels by using the lowest input levels. The desired efficiency level of 100% can only
be achieved if none of the inputs or outputs can be improved without worsening
some of its other inputs or outputs.

In the Charnes, Cooper and Rhodes (CCR) model proposed in 1978, there are n
DMUs to be evaluated, and each DMUj (j = 1, . . . , n) has m inputs (resources)
and s outputs (products), which are denoted with the vectors xj = (x1j, ..., xmj)T
and yj = (y1j, ..., ysj)T , respectively. It should be noted that the focus here is
that of measuring relative efficiency. DEA seeks to maximize the scalar measure
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of efficiency (e0) of the DM U 0, as shown below;
s
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µω
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 > 0 µr , ωr ≥ 0(r = 1, ..., s and i = 1, ..., m)

(1)

where ωi and µr represent i − th input and r − th output weights for DM U0 .
The model above is designed to evaluate the relative performance of some decision making unit (DMU), designated as DM U0 , based on observed performance
of j = 1, 2, ..., n DMUs. A DMU is to be regarded as an entity responsible for
converting inputs into outputs.
The yrj ; xij > 0 in the model are constants which represent observed amounts
of the rth output and the ith input of the j th decision making unit which can
be referred to as DM Uj in a collection of j = 1, ..., n entities which utilize these
i = 1, ..., m inputs and produce these r = 1, ..., s outputs. The numerator of the
above expression represents a set of desired outputs and the denominator represents a collection of resources used to obtain these outputs. The value h0∗ obtained
from this ratio satisfies 0 ≤ h0∗ ≤ 1 and can be interpreted as an efficiency rating in which h0∗ = 1 represents full efficiency and h0∗ ≤ 1 means inefficiency is
present. The sign (∗ ) indicates an optimal value obtained from solving the model.
It is assumed that h0∗ is invariant to the units of measure used for the input and
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output variables. It is also assumed that the data is non-negative and that each
DMU has at least one positive input and output value.
In this regard, Scale Efficiency (SE) measures the impact of the operating scale on
DMU productivity, and is defined as shown below:
SE of DM U =

T echnical Ef f iciency of DM U0
P ure T echnical Ef f iciency of DM U0

CCR Ef f iciency of DM U0
(2)
CCR Ef f iciency of DM U0
Given the above equation, the technical efficiency of a DMU can never exceed its
SE of DM U =

pure technical efficiency. In this way, the overall efficiency or technical efficiency
(CCR) can be decomposed as follows:
CCR = BCC ∗ SE

(3)

The CCR model calculates the technical efficiency (TE), which measures the success of a DMU in producing as large outputs from a given set of inputs (Farrell,
1959). Whereas the BCC model according to Kumar and Gulati (2008), calculates
the pure technical efficiency.
The decomposition expressed above is unique as it indicates the source of inefficiency. In other words, it describes if the inefficiency is caused by inefficient
operation (BCC) or unfavorable circumstances (SE). In some cases, it could be
caused by both factors. It should be noted that the scale efficiency measures the
gap between the efficiency score of a DMU under the Constant Returns to Scale
(CRS) and Variable Returns to Scale (VRS) assumptions. In the CRS assumption,
it is assumed that the firms are operating at an optimal level, while in the VRS,
the firm is assumed to be operating below optimal level.
As required by this study, we adopted the Malmquist Productivity Index (MPI)
first introduced by Fare et al. (1994), to evaluate the efficiency changes between
two time periods. The index is given as:
"

#1
D0t X t+1 , y t+1
D0t+1 X t+1 , y t+1 2
t,t+1
M P I0
=
∗
D0t (X t , y t )
D0t+1 (X t , y t )
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where M P I0t,t+1 is the Malmquist productivity index with output orientation, y
represents the output vector that can be obtained with the resource vector x, and
D0 denotes the distance function. The MPI can be decomposed into technical
efficiency changes and technological frontier changes, in the following way:
"

M P I0t,t+1

D0t+1 X t+1 , y t+1
=
D0t (X t , y t )

# "

D0t X t+1 , y t+1



D0t+1 (X t+1 , y t+1 )

∗

D0t X t , y t



D0t+1 (X t+1 , y t+1 )

#1
2

(5)

Where the first parenthesis measures technical efficiency change (TEC) between
period t and t + 1, the geometric mean of the two ratios in the second parenthesis
measures production frontier change (FC) between two time periods. From the
foregoing, Malmquist index is expressed as:
T EC0t,t+1 ∗ F C0t,t+1

(6)

Thus, T EC0t,t+1 relates to the level of effort that the DMU has been to achieve
efficiency, and measures the capacity of the DMU to shift closer to or further away
from the technological frontier from one time period to the next. Whereas, F C0t,t+1
(technological change index) equals changes in the efficient frontier relative to the
DMU in two time periods and is usually associated with capital investment and
long-term planning strategies.
The DEA was adopted for the study since it does not require a priori assumption
of functional specification relating inputs to outputs and does not demand for the
distributional assumption of the error term.

3.2. Data and Variables
The population of the study constitutes the over 110 pharma-formulation manufacturing facilities in Nigeria (Business Monitor International, 2009). The sample size
consists of twenty (20) pharmaceutical companies (Afrab Chem. Limited, Archy
Pharma Nigeria Ltd., Drugfield Pharmaceuticals Ltd, Ecomed Pharma Ltd., Emzor Pharmaceutical Industries Ltd, Evans Medical Plc, Fidson Healthcare Plc,
Gemini Pharmaceuticals Nig. Ltd., GlaxoSmithKline Nigeria, Juhel Pharma.,
Enugu, May & Baker Nigeria Plc, Mopson Pharmaceutical Industries Ltd, Neimeth
International Pharmaceuticals, Nigerian-German Chemicals Plc, PZ Cussons Plc,
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Ranbaxy Nig. Ltd., Lagos, SKG Pharma Plc., Lagos, Swipha Nigeria Ltd, Swiss
Pharma Nig. Ltd, Lagos, and Vitabiotics Nigeria Ltd) listed on the Nigeria Stock
Exchange between 2012 and 2016. The selection of the sample was based on
availability of a complete panel data between 2012 and 2016. Other firms had
incomplete data or their data was unavailable in the years under consideration.
Secondary data of sales, size (measured by fixed assets), leverage (proxied by Total
Liabilities divided by Total Asset), age of firm (measured by difference between
current year and year of listing), Operating Expenses (sum of Selling expenses,
Distribution cost, Marketing cost, Administrative expenses, Staff cost and Depreciation and amortization in thousands), Cost of sales (Beginning inventory, plus
Purchases, less Ending inventory), Market share (sales over the period and dividing it by the total sales of the industry over the same period), Firm size (total sales
in constant U.S. dollars), Export performance (Exports as a percentage of total
sales), and Sales growth (measured by difference between current and previous
year sales) were extracted from the Annual Reports and Accounts of the selected
companies.

4.0 Results and Discussion
4.1 Descriptive Results
Table 1 shows the descriptive statistics of the variables employed in the study. A
critical view of the table shows that efficiency scores were calculated using one
output variable and three input variables, and as specified in the model, there
were six variables (independent) to measure how firm-specific factors impact on
the efficiency of the employed pharmaceutical firms.
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Table 1: Descriptive Statistics

The average age of pharmaceutical firms in Nigeria was observed to be about 13
years. The table showed that the Nigerian pharmaceutical sector exports about
26% of its produce. These exports are majorly to the ECOWAS countries. The
financial strength of the pharmaceutical sector, as captured by the average leverage ratio, was approximately 3.7%. This is generally low, and it calls for more
financing in this sector. The average market share from the table was 2% since the
industry has many players. The average sales growth is approximately 10%. This
calls for swift attention in the Nigerian pharmaceutical sector. The average values
of the technical efficiency under CRS and VRS assumptions which are 0.64734 and
0.61034, respectively, shows that the pharmaceutical sector in Nigeria is relatively
less efficient and shows that there is need to improve the sector.

4.2 Unit Root Test
The first econometric requirement for estimating a model is that the variables to be
used must be stationary I(0) series. Before testing if the series follow a unit root,
we checked the possibility of cross-sectional dependence in the series which will
likely invalidate the unit root tests. The results obtained from the cross-sectional
dependence (CD) test of Pesaran (2004) are shown below.
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Table 2: Cross-sectional dependence (CD) test

From Table 2, the null hypothesis of no cross-sectional dependence can be strongly
rejected given that the p-value = 0 for all the variables. In the light of this, we applied the cross-sectionally Augmented Dickey-Fuller (CADF) and cross-sectionally
Im-Pesaran-Shin (CIPS) as proposed by Im, et al. (1995) and Harnsen (1995),
respectively. The results from these are presented below.
Table 3: Unit root test

The unit root test results shown above indicate that the variables are I(1) processes. Thus, they were utilized in their first differences.

4.3. Data Envelopment Analysis
Table 4 shows a year-to-year analysis of the various perspectives of efficiency as
well as averages under the CRS and VRS assumptions between 2012 and 2016. It
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also reports the various efficiency changes which include Scale Efficiency Change,
Pure Efficiency Change and Technical Efficiency Change. The averages in the CRS
and VRS assumptions show irregular patterns in the movement of efficiency in the
pharmaceutical sector, with spiral oscillations from year-to-year. From the table,
the SECH (scale efficiency change) shows an average of 0.9558. This value implies
that the pharmaceutical sector in Nigeria is experiencing a decreasing return to
scale in the period under consideration, since the coefficient value of SECH is less
than 1. A decreasing return to scale is also observed in the variable TECH (technical efficiency change).The averages of PECH, EFFCH and TFPCH were 1.0425,
1.1745 and 1.1478 respectively. These values indicated that the pharmaceutical
sector experienced an increasing return to scale during the 2012-2016 period. A
critical analysis of the various efficiency changes shows that inefficiency experienced
in the pharmaceutical sector is scalar in nature (in other words, scale efficiency).
Table 4: Data envelopment analysis results

5.0 Conclusion and Policy Implications
Performance analysis constitutes a major objective of any organization. Owing
to this, the purpose of this study was to assess the efficiency of the pharmaceutical sector in Nigeria. Employing sales as output variable; cost of sales, operating
expenses, and capital as input variables; and age of firm, exports performance,
leverage, market share, firm size, and sales growth as independent variables, the
study found oscillatory movements observed under the CRS and VRS assumptions
from year-to-year. Scale efficiency change and technical efficiency change both experienced a decreasing return to scale indicating an urgent need to address the
issue of efficiency in the pharmaceutical sector.
Given the low penetration of Nigerian pharmaceuticals in the global market, there
is need to improve on the quality and standard of the pharmaceutical sector in
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Nigeria so as to meet up with internationally-accepted standards to facilitate participation and competition with countries such as China, India, Turkey and others.
This is imperative given the negative coefficient of export performance under both
the CRS and VRS assumptions. There is also need to increase financial support
to the sector to aid with technological advancement.
Drawing from the efficiency issues in the Nigerian pharmaceutical industry, the
sector should be reformed and revamped. Governmental health agencies such
as the Federal Ministry of Health, and other health authorities (Pharmacists’
Council of Nigeria (PCN), Pharmaceutical Manufacturing Group of Manufacturers’ Association of Nigeria National Agency for Food and Drug Administration
and Control (NAFDAC)) should reduce registration and administrative costs for
pharmaceutical firms operating in Nigeria. This will allow local firms to produce
quality medicines that can compete internationally. This can be done via improved
biotechnology and development of new phytomedicines using locally sourced raw
materials which requires a sizeable investment in Research and Development.
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